Gout Market Research Report Forecast till 2030

List of Tables

Market Overview

Gout Market is anticipated to register a significant CAGR of 11.75% during the review period.

Gout is a kind of provocative joint pain that influences men beyond 40 a year old, have a high measure of uric corrosive in their blood. As per studies, its commonness and frequency have expanded over the most recent couple of many years. The rising commonness of gout because of changing way of life designs and the developing geriatric populace is supposed to help market development over the gauge period. For example, according to the article distributed by the Records of Rheumatic Sicknesses in June 2021, a cross country companion concentrates on utilizing information from the Clinical Practice Research Datalink, from 1997 to across the Coronavirus pandemic in 2021 saw that the predominance pace of gout has expanded from 0.98%in 1997 to 2.33% in 2021. Notwithstanding, as per a similar source, the frequency of gout expanded by 0.98/1,000 people in UK 2021. Thusly, the weight of gout is supposed to build the interest in drugs treating this condition, which is expected to impel the market development over the estimate period.

Market Segmentation

The Gout Market segmentation, based on treatment and diagnosis, includes diagnosis, treatment. The treatment segment is further sub segmented into NSAIDs, corticosteroids, colchicine, urate-lowering agents, and others.

The Gout Market segmentation is based on applications that include acute gout and chronic gout. The Gout Market segmentation is based on hospitals & clinics, specialty centers, and others.

Regional Insights

The North America region fragmented into US, and Canada. The North America region held the biggest market share in the Gout Endlessly market is represented USD 1.80 billion of every 2022 and is supposed to display a 12.03% CAGR during the review time frame. Further, in the North America region the US gout market represented the biggest market share. This is credited to the rising predominance of gout, developing reception of biologics, and rising Research and development exercises on regenerative prescriptions.

Europe gout market is supposed to represent the second-biggest market share because of the availability to cutting edge finding and treatment offices, the rising geriatric populace inclined to gout is driving up interest for powerful treatment and therapeutics and developing medical care consumption. The Asia-Pacific gout market is supposed to develop at a CAGR of 13.12% from 2023 to 2030. This is because of variables like further developing medical care framework, developing speculation by central parts with neighbourhood producers, and the rising patient populace experiencing gout.

The Rest of the World incorporates the Middle East, Africa, and Latin America. Middle East hold the significant market share in middle east and Africa region because of restricted medical care framework, a shortage of mindfulness regarding the side effects of the sickness, and an absence of talented experts to make gout therapeutics drugs are restricting the development of the gout market in Sub-Saharan Africa.

Major Players

Key Companies in the Gout Market are Novartis AG (Switzerland), Lannett (US), Horizon Therapeutics plc (US), Takeda Pharmaceutical Company Limited (Japan), GlaxoSmithKline plc (UK), Regeneron Pharmaceuticals, Inc (US), Teijin Limited (Japan), Viatris Inc (US), Boehringer Ingelheim International GmbH (Germany), and ROMEG Therapeutics, LLC (US).

Product Code: MRFR/HC/4453-CR

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 13

1.1 OVERVIEW 13

2 MARKET INTRODUCTION 14

2.1 DEFINITION 14
2.2 SCOPE OF THE STUDY 14
2.3 RESEARCH OBJECTIVE 14
2.4 MARKET STRUCTURE 15
2.5 ASSUMPTIONS & LIMITATIONS 15

3 RESEARCH METHODOLOGY 16

3.1 DATA MINING 16
3.2 SECONDARY RESEARCH 17
3.3 PRIMARY RESEARCH 18
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19
3.5 FORECASTING TECHNIQUES 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
- 3.6.1 BOTTOM-UP APPROACH 22
- 3.6.2 TOP-DOWN APPROACH 22
3.7 DATA TRIANGULATION 23
3.8 VALIDATION 23

4 MARKET DYNAMICS 24

4.1 OVERVIEW 24
4.2 DRIVERS 25
- 4.2.1 INCREASING PREVALENCE OF GOUT 25
- 4.2.2 RISING HEALTHCARE EXPENDITURE 25
- 4.2.3 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 26
4.3 RESTRAINTS 27
- 4.3.1 SIDE EFFECTS OF GOUT THERAPEUTIC DRUGS 27
- 4.3.2 LACK OF AWARENESS AMONG PEOPLE 28
4.4 OPPORTUNITY 28
- 4.4.1 RISING NUMBER OF STRATEGIC INITIATIVES 28

5 MARKET FACTOR ANALYSIS 29

5.1 VALUE CHAIN ANALYSIS 29
- 5.1.1 R&D 30
- 5.1.2 MANUFACTURING 30
- 5.1.3 DISTRIBUTION & SALES 30
- 5.1.4 POST-SALES MONITORING 30
5.2 PORTER'S FIVE FORCES MODEL 31
- 5.2.1 THREAT OF NEW ENTRANTS 31
- 5.2.2 BARGAINING POWER OF SUPPLIERS 32
- 5.2.3 THREAT OF SUBSTITUTES 32
- 5.2.4 BARGAINING POWER OF BUYERS 32
- 5.2.5 INTENSITY OF RIVALRY 32
5.3 IMPACT OF COVID-19 ON THE GLOBAL GOUT MARKET 33
- 5.3.1 IMPACT ON VALUE CHAIN 33
- 5.3.2 IMPACT ON SUPPLY CHAIN 33
- 5.3.3 IMPACT ON KEY PLAYERS 33

6 GLOBAL GOUT MARKET, BY DIAGNOSIS & TREATMENT 34

6.1 OVERVIEW 34
6.2 DIAGNOSIS 36
6.3 TREATMENT 36
- 6.3.1 NSAIDS 37
- 6.3.2 CORTICOSTEROIDS 37
- 6.3.3 COLCHICINE 38
- 6.3.4 URATE-LOWERING AGENTS 38
- 6.3.5 OTHERS 39

7 GLOBAL GOUT MARKET, BY APPLICATION 40

7.1 OVERVIEW 40
7.2 ACUTE GOUT 41
7.3 CHRONIC GOUT 42

8 GLOBAL GOUT MARKET, BY END USER 43

8.1 OVERVIEW 43
8.2 HOSPITALS & CLINICS 44
8.3 SPECIALTY CENTERS 45
8.4 OTHERS 45

9 GLOBAL GOUT MARKET, BY REGION 46

9.1 OVERVIEW 46
9.2 NORTH AMERICA 48
- 9.2.1 US 50
- 9.2.2 CANADA 51
9.3 EUROPE 52
- 9.3.1 GERMANY 54
- 9.3.2 UK 55
- 9.3.3 FRANCE 56
- 9.3.4 ITALY 57
- 9.3.5 SPAIN 58
- 9.3.6 REST OF EUROPE 59
9.4 ASIA-PACIFIC 61
- 9.4.1 CHINA 63
- 9.4.2 JAPAN 64
- 9.4.3 INDIA 65
- 9.4.4 AUSTRALIA 66
- 9.4.5 SOUTH KOREA 67
- 9.4.6 REST OF ASIA PACIFIC 68
9.5 REST OF THE WORLD 69
- 9.5.1 MIDDLE EAST 71
- 9.5.2 AFRICA 72
- 9.5.3 LATIN AMERICA 73

10 COMPETITIVE LANDSCAPE 74

10.1 OVERVIEW 74
10.2 COMPETITIVE BENCHMARKING 75
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL GOUT MARKET 76
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL GOUT MARKET 77
10.5 KEY DEVELOPMENT ANALYSIS 77
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 78
- 10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL 78
- 10.6.2 PARTNERSHIPS/ AGREEMENTS 78
10.7 FINANCIAL MATRIX 78
- 10.7.1 SALES (USD MILLION), 2022 78
- 10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022 79

11 COMPANY PROFILES 80

11.1 NOVARTIS AG 80
- 11.1.1 COMPANY OVERVIEW 80
- 11.1.2 FINANCIAL OVERVIEW 81
- 11.1.3 PRODUCTS OFFERED 81
- 11.1.4 KEY DEVELOPMENTS 81
- 11.1.5 SWOT ANALYSIS 82
- 11.1.6 KEY STRATEGIES 82
11.2 LANNETT 83
- 11.2.1 COMPANY OVERVIEW 83
- 11.2.2 FINANCIAL OVERVIEW 83
- 11.2.3 PRODUCTS OFFERED 84
- 11.2.4 KEY DEVELOPMENTS 84
- 11.2.5 KEY STRATEGIES 84
11.3 HORIZON THERAPEUTICS PLC 85
- 11.3.1 COMPANY OVERVIEW 85
- 11.3.2 FINANCIAL OVERVIEW 86
- 11.3.3 PRODUCTS OFFERED 86
- 11.3.4 KEY DEVELOPMENTS 86
- 11.3.5 KEY STRATEGIES 87
11.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED 88
- 11.4.1 COMPANY OVERVIEW 88
- 11.4.2 FINANCIAL OVERVIEW 88
- 11.4.3 PRODUCTS OFFERED 89
- 11.4.4 KEY DEVELOPMENTS 89
- 11.4.5 KEY STRATEGIES 89
11.5 GLAXOSMITHKLINE PLC 90
- 11.5.1 COMPANY OVERVIEW 90
- 11.5.2 FINANCIAL OVERVIEW 91
- 11.5.3 PRODUCTS OFFERED 91
- 11.5.4 KEY DEVELOPMENTS 91
- 11.5.5 SWOT ANALYSIS 92
- 11.5.6 KEY STRATEGIES 92
11.6 REGENERON PHARMACEUTICALS, INC. 93
- 11.6.1 COMPANY OVERVIEW 93
- 11.6.2 FINANCIAL OVERVIEW 93
- 11.6.3 PRODUCTS OFFERED 94
- 11.6.4 KEY DEVELOPMENTS 94
- 11.6.5 KEY STRATEGIES 94
11.7 TEIJIN LIMITED 95
- 11.7.1 COMPANY OVERVIEW 95
- 11.7.2 FINANCIAL OVERVIEW 95
- 11.7.3 PRODUCTS OFFERED 96
- 11.7.4 KEY DEVELOPMENTS 96
- 11.7.5 SWOT ANALYSIS 96
- 11.7.6 KEY STRATEGIES 96
11.8 VIATRIS INC. 97
- 11.8.1 COMPANY OVERVIEWS 97
- 11.8.2 FINANCIAL OVERVIEW 98
- 11.8.3 PRODUCTS OFFERED 98
- 11.8.4 KEY DEVELOPMENTS 98
- 11.8.5 SWOT ANALYSIS 99
- 11.8.6 KEY STRATEGIES 99
11.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. 100
- 11.9.1 COMPANY OVERVIEW 100
- 11.9.2 FINANCIAL OVERVIEW 101
- 11.9.3 PRODUCTS OFFERED 101
- 11.9.4 KEY DEVELOPMENTS 102
- 11.9.5 SWOT ANALYSIS 102
- 11.9.6 KEY STRATEGIES 102
11.10 ROMEG THERAPEUTICS, LLC 103
- 11.10.1 COMPANY OVERVIEW 103
- 11.10.2 FINANCIAL OVERVIEW 103
- 11.10.3 PRODUCTS OFFERED 103
- 11.10.4 KEY DEVELOPMENTS 103
- 11.10.5 KEY STRATEGIES 103

12 APPENDIX 104

12.1 REFERENCES 104
12.2 WORLD HEALTH ORGANIZATION 104
12.3 THE GOUT EDUCATION SOCIETY 104
12.4 ARTHRITIS FOUNDATION 104
12.5 AMERICAN ARTHRITIS SOCIETY 104
12.6 SOUTH AFRICAN RHEUMATISM AND ARTHRITIS ASSOCIATION (SARAA) 104
12.7 EMIRATES ARTHRITIS FOUNDATION 104
12.8 ARTHRITIS FOUNDATION OF ASIA 104
12.9 OSTEOARTHRITIS RESEARCH SOCIETY INTERNATIONAL (OARSI) 104
12.10 SOAR - SOCIETY FOR OSTEOARTHRITIS RESEARCH 104
12.11 THE EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY 104
12.12 RELATED REPORTS 105